Claims

1. Pharmaceutical suspension formulation comprising
   a. particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
   b. particles of ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and
   c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

2. Pharmaceutical suspension formulation according to claim 1 consisting of

   a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
   b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
   c. ethanol,
   d. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
   e. optionally a surfactant.

3. Suspension formulation according to any of the proceeding claims containing less than 3% by weight of ethanol.

4. Pharmaceutical suspension formulation according to claim 1 consisting of

   a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
   b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
   c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
   d. a surfactant.

5. Suspension formulation according to any of the proceeding claims containing R,R-formoterol.

6. Suspension formulation according to any of the proceeding claims containing formoterol fumarate dihydrate.

7. Suspension formulation according to any of the proceeding claims containing oleic acid as surfactant.

8. Suspension formulation according to any of the proceeding claims containing about 0.001 to 0. 1 % (w/w) of oleic acid.

9. Suspension formulation according to any of the proceeding claims containing HFA 227 as propellant.

10. Suspension formulation according to claim 1 containing disodium chromoglycate at concentrations, which are not therapeutically and/or prophylactically active.

11. Suspension formulation according to claim 1, which is administered in once daily dosing regimen.